Early Discharge Check List to be Minimalist

Alan C. Yeung, MD Li Ka Shing Professor of Medicine Chief, Division of Cardiovascular Medicine Stanford University School of Medicine



Disclosure Statement of Financial Interest

Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.

Affiliation/Financial Relationship

- Grant/Research Support
- Grant/Scientific Advisory Board
- Executive Physician Council

Company

- Edwards Lifesciences
- Medtronic
- Boston Scientific Corp



Commercial TAVR case

G.K.

MRN XXXXXX-X

Proposed Treatment Fast 8/9/2016

Referring MD: Mike McConnell, MD THV MDs: MPF/BF

Track Eligible: Yes

History: 78 year old male with history of HTN, OSA, and severe, symptomatic AS. History SVT and NSVT on Ziopatch 2013. History of CLL since 2012; Rai stage 0 and no treatment indicated. History of polio at 19 yrs with post-polio syndrome. Currently symptomatic of dizziness associated with nausea, syncope x 2, exertional dyspnea, PND, chest discomfort, and chronic fatigue.

PFTs:	FEV1	2.2 L (83%)	Frailty:	BMI	38.3	STS	2.0%		
	DLCO	-	Serum A	lbumin	3.5 g/dL (-)				
				ADLs	4/6 (+)	A			
Anticoagulation History/Regimen:			Grip St	trength	13 kg (+)	Age 78, ma	Age 78, male, Caucasian, 125 kg, 180.7 cm (BSA 2.50), Cr		
				5m WT	7.8 sec (+)	1.32, HIN,	NYHA Class III, EF 62%, AS, trace AI, moderate		
Aspirin 162 mg daily				Score	3/4	INIR, trace	i k, first op, elective		

Proposed: Extreme Risk (Frailty) Commercial TAVR, 26 mm Sapien 3, Transfemoral approach, Right side

	Echo: D	ate	RHC:	RA	2	Coronary heights:	LCA	17.2 mm	SOV Diameters:	RCC	34.6
	6/20/2016			RV	30/3		RCA	15.9 mm	mm		
	AVA	0.72 cm2		PA	33/8					LCC	36.9
	AVAI	0.29 cm²/m²		PCW	8	Vascular access:	RCIA	11.2 x		mm	
	V2 Max	4.0 m/sec		со	6.95	9.2				NCC	36.5
	Gradient	41 mmHg		CI	2.9	(in mm)	REIA #1	7.9 x 7.7		mm	
	V1/V2	-	Cors:	LM	none	1	REIA #2	8.1 x 7.9	SOV heights > 15 mm:	Yes	
	EF	62%					RCFA	8.2 x 7.5	Ascending Ao diameter: L	ong Axis	35.5 mm
	RVSP	31 mmHg		LAD	minor irreg	gularities	LCIA	11.1 x		Short Ax	i s 35.0 mm
	AI	trace		10.1					Annulus:	Diamete	r ~25.8
	MR	mild-		LCX	minor irre	gularities	LEIA	#1 8.3 x	mm Long Axis 30.1 mm S	hort Axis	21.2 mm
	moderate			7.8					Area	489 mm ²	2
Notes:	_TR	trace		RCA	minor irre	gularities	LEIA	#2 8.3 x		Perimete	er 81.6 mm
				8.0		1					
				Grafts	-		LCFA	7.9 x 7.7			
Summary: • 78 year old ma		ale				 Transfer 	noral appro	ach			
 STS 2.0% Extreme Risk (Frailty) Comr 26 mm Sapien 3 THV 						 Right sid 	le				
			Frailty) Commercial TAVR				• Fast Trac	ck eligible			
			3 THV				•				



Patient Flow in HIGH Risk TAVR



Patient Flow in LOW Risk TAVR



What's Next? Efficiency and Economics: Minimalist TF TAVR





May 2015

- Sept 2007
- Simplify procedure
- No General Anesthesia, No TEE
- Maintain superior outcomes, short and long term
- Decrease resource utilization and cost





Some Data with EW Sapien

JACC: CARDIOVASCULAR INTERVENTIONS © 2014 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION PUBLISHED BY ELSEVIER INC. VOL. 7, NO. 8, 2014 ISSN 1936-8798/\$36.00 http://dx.doi.org/10.1016/j.jcin.2014.04.005

Comparison of Transfemoral Transcatheter Aortic Valve Replacement Performed in the Catheterization Laboratory (Minimalist Approach) Versus Hybrid Operating Room (Standard Approach)

Outcomes and Cost Analysis

Vasilis Babaliaros, MD,* Chandan Devireddy, MD,* Stamatios Lerakis, MD,* Robert Leonardi, MD,* Sebastian A. Iturra, MD,† Kreton Mavromatis, MD,* Bradley G. Leshnower, MD,† Robert A. Guyton, MD,† Mihir Kanitkar, MD,* Patricia Keegan, NP,* Amy Simone, PA,† James P. Stewart, MD,* Nima Ghasemzadeh, MD,* Peter Block, MD,* Vinod H. Thourani, MD†

JACC: CARDIOVASCULAR INTERVENTIONS CME



TVT 2016 A Multidisciplinary Heart Team Approach



Mid-Term Mortality with Minimalist Approach





Cost Saving with Minimalist Approach











Who Is a Minimalist Candidate?





ardiovascular

Evolution of TF Minimalist TAVR





© TVT 2016 Transcatheter Valve Therapies (TVT) A Multidisciplinary Heart Team Approach





Partnership with Nursing and Staff

Nurse and Staff Champions Cath Lab to Floor protocol: No Neurologic events No drips No vascular complications No heart block *New LBBB was OK **Procedure specific Care Plans:** Early Ambulation Protocol- 4 hrs **General Diet-immediate**

ICU Utilization <10%





Minimalist Early Discharge POD 1

Procedure Details and Outcomes

	All (N=411)	Early Discharge (N=82)	Standard Discharge (N=329)	P value
Valve type, N (%)				
Sapien	103 (25.1)	4 (4.6)	99 (30.1)	< 0.001
Sapien XT	198 (48.2)	39 (47.6)	159 (48.3)	
Sapien 3	110 (26.8)	39 (47.6)	71 (21.6)	
Major vasc complication	13 (3.2)	0 (0.0)	13 (4.0)	0.08
Minor vasc complication	36 (8.8)	3 (3.7)	33 (10.1)	0.08
Pacemaker need	29 (8.4)	0 (0.0)	29 (10.6)	0.001
Major stroke	7 (1.7)	0 (0.0)	7 (2.1)	0.35
30 Day Readmissions	24 (5.8)	4 (4.9)	20 (6.1)	0.80
30 day Mortality	3 (0.7)	1 (1.2)	1 (0.3)	0.36
30 day PVL				
None	232 (58.4)	56 (71.8)	177 (55.1)	0.03
Mild	140 (35.1)	18 (23.1)	122 (38.0)	
Moderate/Severe	26 (6.5)	4 (5.1)	22 (6.9)	





Expedited Minimalist TAVR-Same Day Admit & Next Day Discharge



Anesthesia Selection Over Time from TVT Registry



Analysis Outcomes of Minimalist from TVT registry

Courtesy Jay Giri, UPENN

	Moderate Sedation	General Anesthesia	Odds Ratio	P-value
30-Day Mortality	2.96%	4.01%	0.72	P<0.001
30-Day Death/Str oke	4.80%	6.36%	0.69	P<0.001



Translating Science to Practice

Minimalist in Severe COPD: Mortality Benefit?









Conclusions

- •Minimalist TAVR is the strategy on which next day discharge and lower costs will be more common.
- •Minimalist TAVR may have a mortality benefit in HR patients with significant comorbidities
- •Anatomical Risk (not clinical risk) will be the dividing line on whether patients are done Minimalist TAVR (>80%)



